Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Accumulated clinical and experimental data suggest that dysfunctional coronary
microcirculation plays a pivotal role in the progression of heart failure despite an optimal
therapy used. Therefore, we hypothesize that improvement in microvascular function by calcium
antagonist, verapamil may result in additional clinical benefit. Thus, the aim of this study
is to compare the effect of treatment with verapamil or carvedilol on long-term outcomes in
stable, chronic heart failure secondary to non-ischemic cardiomyopathy.